 WOBURN, Mass., Jan. 03, 2023 GLOBE NEWSWIRE -- Replimune Group, Inc. Nasdaq: REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 AM PT at the Westin St. Francis Hotel in San Francisco, CA. 